Plain-English translation of NCT06077760 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new treatment approach for people with non-small cell lung cancer who have had surgery to remove their tumor. The trial compares (a personalized mRNA vaccine designed specifically for each patient's cancer) combined with (an immunotherapy drug) against alone. The goal is to see if adding the vaccine helps keep cancer from returning after surgery.
Even after successful surgery, lung cancer can come back in many patients. This medication is designed to train your immune system to recognize and fight any remaining cancer cells, potentially preventing recurrence and improving long-term survival.
If you join this trial, you will receive either the new vaccine plus immunotherapy or immunotherapy alone (decided randomly). You'll come in for injections every 3 weeks and intravenous infusions every 6 weeks, for up to about one year total, unless your cancer returns or you experience unacceptable side effects. The study team will monitor you closely with regular visits and tests to check how well the treatment is working and how you are tolerating it.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States